CGT4255

Cogent Biosciences, Inc. · Phase 1 active Small molecule

At a glance

Generic name	CGT4255
Sponsor	Cogent Biosciences, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CGT4255 CI brief — competitive landscape report
CGT4255 updates RSS · CI watch RSS
Cogent Biosciences, Inc. portfolio CI